Molecular and Growth-Based Drug Susceptibility Testing ofMycobacterium tuberculosisComplex for Ethambutol Resistance in the United States
| العنوان: | Molecular and Growth-Based Drug Susceptibility Testing ofMycobacterium tuberculosisComplex for Ethambutol Resistance in the United States |
|---|---|
| المؤلفون: | David Sikes, Beverly Metchock, Denise Hartline, Allison McAlister, Angela M. Starks, Jeffrey Driscoll, Mitchell A. Yakrus |
| المصدر: | Tuberculosis Research and Treatment Tuberculosis Research and Treatment, Vol 2016 (2016) |
| بيانات النشر: | Hindawi Limited, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Drug, Tuberculosis, Article Subject, biology, business.industry, media_common.quotation_subject, lcsh:R, 030106 microbiology, lcsh:Medicine, Drug susceptibility, Drug resistance, medicine.disease, biology.organism_classification, DNA sequencing, Microbiology, 03 medical and health sciences, Mycobacterium tuberculosis complex, medicine, business, Gene, Ethambutol, Research Article, medicine.drug, media_common |
| الوصف: | Ethambutol (EMB) is used as a part of drug regimens for treatment of tuberculosis (TB). Susceptibility ofMycobacterium tuberculosiscomplex (MTBC) isolates to EMB can be discerned by DNA sequencing to detect mutations in theembBgene associated with resistance. US Public Health Laboratories (PHL) primarily use growth-based drug susceptibility test (DST) methods to determine EMB resistance. The Centers for Disease Control and Prevention (CDC) provides a service for molecular detection of drug resistance (MDDR) by DNA sequencing and concurrent growth-based DST using agar proportion. PHL and CDC test results were compared for 211 MTBC samples submitted to CDC from September 2009 through February 2011. Concordance between growth-based DST results from PHL and CDC was 88.2%. A growth-based comparison of 39 samples, where anembBmutation associated with EMB resistance was detected, revealed a higher percentage of EMB resistance by CDC (84.6%) than by PHL (59.0%) which was significant (Pvalue = 0.002). Discordance between all growth-based test results from PHL and CDC was also significant (Pvalue = 0.003). Most discordance was linked to false susceptibility using the BACTEC™MGIT™960 (MGIT) growth-based system. Our analysis supports coalescing growth-based and molecular results for an informed interpretation of potential EMB resistance. |
| وصف الملف: | text/xhtml |
| تدمد: | 2090-1518 2090-150X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083fcbdb91687499cf76a1fe321d6742 https://doi.org/10.1155/2016/3404860 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....083fcbdb91687499cf76a1fe321d6742 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20901518 2090150X |
|---|